Re-inventing Drug Development
portes grátis
Re-inventing Drug Development
Handen, Jeffrey S.
Taylor & Francis Ltd
10/2024
152
Mole
9781032929996
Pré-lançamento - envio 15 a 20 dias após a sua edição
Descrição não disponível.
Redefining Innovation. Collaborations of the Future. Portfolio Management: Selecting Right "Set Of Projects" to Meet Product Development Goals. Funding and Resourcing Clinical Development. Emerging Role of Patients in Clinical Research. Innovative Organizations: Viewpoint of Organizational Scholars and Practitioners. Moving Toward Personalized Medicine; How to Transform Product Development.
Este título pertence ao(s) assunto(s) indicados(s). Para ver outros títulos clique no assunto desejado.
Drug Development;Patient Advocacy Groups;clinical;Personalized Medicine;contract;Product Development Model;research;Portfolio Management;organization;Patient Involvement;patient;FDA Initiative;advocacy;Accountable Care Organizations;groups;Drug Development Process;portfolio;ODAC;manager;EHR System;process;Myeloma Patients;Ph Ar;ONJ Case;Outsourcing Firms;Company's Strategic Goals;Translational Research;Portfolio Prioritization;CRO Industry;Targeted Therapy Approach;Biologics License Applications;Clinical Research Enterprise;Biopharmaceutical Companies;Clinical Trial Patients;Pharmaceutical Development Process
Redefining Innovation. Collaborations of the Future. Portfolio Management: Selecting Right "Set Of Projects" to Meet Product Development Goals. Funding and Resourcing Clinical Development. Emerging Role of Patients in Clinical Research. Innovative Organizations: Viewpoint of Organizational Scholars and Practitioners. Moving Toward Personalized Medicine; How to Transform Product Development.
Este título pertence ao(s) assunto(s) indicados(s). Para ver outros títulos clique no assunto desejado.
Drug Development;Patient Advocacy Groups;clinical;Personalized Medicine;contract;Product Development Model;research;Portfolio Management;organization;Patient Involvement;patient;FDA Initiative;advocacy;Accountable Care Organizations;groups;Drug Development Process;portfolio;ODAC;manager;EHR System;process;Myeloma Patients;Ph Ar;ONJ Case;Outsourcing Firms;Company's Strategic Goals;Translational Research;Portfolio Prioritization;CRO Industry;Targeted Therapy Approach;Biologics License Applications;Clinical Research Enterprise;Biopharmaceutical Companies;Clinical Trial Patients;Pharmaceutical Development Process
